REVELATION BIOSCIENCES, INC.
For the period ended Dec 31, 2025. Filed Feb 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 26, 2026
REVB$4.11+5.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock · Additional Paid-in · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2023 (as previously reported) | 16,484 | $16 | $32,114,801 | $(25,467,102) | $6,647,715 |
| Retrospective application of reverse recapitalization | (15,138) | (15) | 15 | — | — |
| Reverse stock split fractional stock round up | 25 | — | — | — | — |
| Balance at December 31, 2023 | 1,371 | 1 | 32,114,816 | $(25,467,102) | $6,647,715 |
| Issuance of common stock from the February 2024 Public Offering | 670 | 1 | 5,417,052 | — | 5,417,053 |
| Class D Pre-Funded Warrants exercises | 6,441 | 6 | 121 | — | 127 |
| Alternative cashless exercise of Class C Common Stock Warrants | 18 | — | 57,589 | — | 57,589 |
| Common stock issued for services | 55 | — | 25,000 | — | 25,000 |
| Class D Common Stock Warrants exercises | 526 | 2 | 241,388 | — | 241,390 |
| Class D Warrant Inducement exercises | 13,271 | 13 | 3,501,263 | — | 3,501,276 |
| Class E Common Stock Warrant Inducement exercises | 21,174 | 21 | 3,687,897 | — | 3,687,918 |
| Stock-based compensation expense | — | — | 168,850 | — | 168,850 |
| Net loss | — | — | — | (15,038,536) | (15,038,536) |
| Balance as of December 31, 2024 | 43,526 | $44 | $45,213,976 | $(40,505,638) | $4,708,382 |
| Balance as of December 31, 2024 (as previously reported) | 522,223 | $522 | $45,213,498 | $(40,505,638) | $4,708,382 |
| Retrospective application of reverse recapitalization | (478,724) | (478) | 478 | — | — |
| Reverse stock split fractional stock round up | 27 | — | — | — | — |
| Balance at December 31, 2024 | 43,526 | 44 | 45,213,976 | (40,505,638) | 4,708,382 |
| Alternative cashless exercise of Class F Common Stock Warrants | 42,336 | 42 | (42) | — | — |
| Issuance of RSA's | 252,937 | 253 | (253) | — | — |
| Issuance of common stock from the May 2025 Public Offering | 56,250 | 56 | 3,388,188 | — | 3,388,244 |
| Class H Pre-Funded Warrants exercises | 247,084 | 247 | 50 | — | 297 |
| Class H Common Stock Warrants exercises | 41,250 | 41 | 362,959 | — | 363,000 |
| Class H Warrant Inducement exercises | 900,584 | 901 | 8,718,452 | — | 8,719,353 |
| Issuance of common stock for rollover RSU awards | 2 | — | — | — | — |
| Stock-based compensation expense | — | — | 595,368 | — | 595,368 |
| Net loss | — | — | — | (8,913,649) | (8,913,649) |
| Balance as of December 31, 2025 | 1,583,969 | $1,584 | $58,278,698 | $(49,419,287) | $8,860,995 |
| Year EndedDecember 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(8,913,649) | $(15,038,536) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 595,368 | 168,850 |
| Depreciation expense | 27,058 | 27,923 |
| Non-cash lease expense | 18,630 | — |
| Loss on disposal of equipment | 11,207 | — |
| Change in fair value of warrant liability | (2,158) | (81,441) |
| Issuance of common stock for services | — | 25,000 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (44,598) | 17,992 |
| Deferred offering costs | — | 71,133 |
| Other assets | (30,941) | — |
| Accounts payable | (206,120) | (576,277) |
| Accrued expenses | 269,756 | (2,935,920) |
| Operating lease liability | 5,866 | — |
| Net cash used in operating activities | (8,269,581) | (18,321,276) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | — | (19,171) |
| Net cash used in investing activities | — | (19,171) |
| Cash flows from financing activities: | ||
| Proceeds from the May 2025 Public Offering, net | 3,388,244 | — |
| Proceeds from Class H Pre-Funded Warrants exercises | 297 | — |
| Proceeds from the Class H Common Stock Warrants exercises | 363,000 | — |
| Proceeds from Warrant Inducement exercises, net | 8,719,353 | 3,501,276 |
| Proceeds from the February 2024 Public Offering, net | — | 5,417,053 |
| Proceeds from the Class D Common Stock Warrants exercises | — | 241,390 |
| Proceeds from Class D Pre-Funded Warrants exercises | — | 127 |
| Proceeds from the Class E Common Stock Warrants exercises | — | 3,687,918 |
| Net cash provided by financing activities | 12,470,894 | 12,847,764 |
| Net increase (decrease) in cash and cash equivalents | 4,201,313 | (5,492,683) |
| Cash and cash equivalents at beginning of period | 6,499,018 | 11,991,701 |
| Cash and cash equivalents at end of period | $10,700,331 | $6,499,018 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Alternative cashless exercises of Class F Common Stock Warrants | $4,104,680 | $— |
| Fair Value of Class H Common Stock Warrants in connection with the May 2025 Public Offering | $11,546,080 | $— |
| Fair Value of Class I Common Stock Warrants in connection with the Class H Warrant Inducement | $23,686,845 | $— |
| Incremental fair value of the Class H Common Stock Warrants in connection with the Class H Warrant Inducement | $91,455 | $— |
| Deemed dividend for exercise price reductions of warrants | $5,951,528 | $— |
| Operating lease right-of-use asset exchanged for lease liability | $740,918 | $— |
| Fair Value of Class G Common Stock Warrants | $— | $2,066,429 |
| Fair Value of Class F Common Stock Warrants | $— | $4,104,680 |
| Fair Value of Class E Common Stock Warrants in connection with the Class D Warrant Inducement | $— | $4,887,683 |
| Incremental fair value of the Class D Common Stock Warrants in connection with the Class D Warrant Inducement | $— | $939,679 |
| Equity issuance costs in connection with the Class D Warrant Inducement included in accounts payable | $— | $25,968 |
| Fair Value of Class D Common Stock Warrants in connection with the February 2024 Public Offering | $— | $6,269,684 |
| Alternative cashless exercise of Class C Common Stock Warrants | $— | $57,589 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.